Fintel reports that on April 22, 2025, Cantor Fitzgerald initiated coverage of Amgen (NasdaqGS:AMGN) with a Overweight ...

Cantor Fitzgerald analyst Carter Gould downgraded Amgen (AMGN) to Neutral from Overweight with a price target of $305, down from $340, as the ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio, with significant contributions from rare disease treatments and biosimilars. Financially robust, Amgen ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

In the latest trading session, Amgen (AMGN) closed at $277.29, marking a -1.89% move from the previous day. This change lagged the S&P 500's 0.13% gain on the day. At the same time, the Dow lost 1 ...

Amgen made considerable strides in its oncology portfolio, as evidenced by the successful interim results for its DeLLphi-304 trial assessing IMDELLTRA for small cell lung cancer. These product ...

In his 13 years as CEO at Amgen, Robert Bradway has seen many of his counterparts at other major biopharma companies come and go. A major part of the reason Bradway, 62, has remained in charge at ...

Shares of UnitedHealth and Amgen are posting losses Thursday morning, propelling the Dow Jones Industrial Average selloff. Supported by world-class markets data from Dow Jones and FactSet ...

The Dow Jones Industrial Average is declining Wednesday morning with shares of Amgen and Merck seeing the biggest losses for the price-weighted average. Supported by world-class markets data from ...